AYOXXA Biosystems (Cologne, Germany and Singapore) closed a € 9m Series B round of financing. Beside the new investors Creathor Venture, b-to-v Partners and HR Ventures all of the company's existing investors (Wellington Partners, High-Tech Gründerfonds, KFW, NRW.BANK and others) took part. In addition several private investors from the US and Europe, including AYOXXA employees and two of the Qiagen founders, joined this financing round.
In line with the company's strategy to commercialize its novel in-situ encoded bead array technology (IEBA), the funding will be used to scale-up the production of AYOXXA's proprietary biochips as well as to achieve international commercial readiness.
"I am pleased that we were able to close this round in a macro- environment that currently is very challenging, finding funding for young companies has become extremely difficult.", comments Dr. Andreas Schmidt, CEO of AYOXXA, "Beyond the financial assets, we will benefit from the expanded network in the biotechnology, pharmaceutical and enabling technology field. This will facilitate effective commercialization of our IEBA technology in the near future." he adds.
"The overall concept of AYOXXA has convinced us and the patented new multiplex platform already generates big interest in the pharmaceutical and biotech industries. The combination of innovative biotechnology and information technology also fits well with Creathor's investment strategy", says Karlheinz Schmelig, Managing Partner at Creathor Venture.
"The international team, a high-performance, easy-to-use platform and a renowned investor base will help AYOXXA to develop their technology to a gold standard in protein research. I am looking forward to work with the AYOXXA team as an advisory board member", adds Christian Leikert, Investment Manager at Creathor Venture In order to complement the co-founders Dr. Andreas Schmidt (CEO) and Prof. Dieter Trau (CSO) AYOXXA has attracted experienced leadership for its corporate executive management team and supervisory board:
Dr. Markus Zumbansen, Vice President Research and Development, has more than ten years of experience in the development of platform technologies. Before joining AYOXXA he worked in different R&D positions within the biotech industry, Miltenyi Biotec being his last station.
Michael Rasche, newly appointed Corporate Vice President Global Commercial Operations is now leading all activities in the area of marketing, sales and business development. He has an international background with 23 years of experience in leading pharma and diagnostics companies.
Rodney Turner, until recently Vice President of Corporate Business Development for Life Technologies Corporation, joins AYOXXA's supervisory board as of immediately. Mr. Turner graduated with a BA from Rice University. He had a leading role in the acquisitions of AMG Advanced Microscopy Group, BAC The Bioaffinity Company, BioTrove, Stokes Bio, GeneArt AG, Ambion, and several others. His extensive experience in life science tools companies will primarily help to accelerate product introduction into new markets across the research segments.
About AYOXXA Biosystems
AYOXXA Biosystems, an international biotech company based in Cologne, Germany and Singapore has developed a proprietary Technology platform for multiplexed protein analysis. Core to the cutting-edge system is a bead-based technology that yields 10,000-fold more data points than a standard ELISA. Together with the lowest sample volume in multiplex protein analysis history, very good accuracy and data robustness, high data throughput and readout with equipment existing already in your lab, AYOXXA will innovate biomedical research, pharmacological screening and preclinical diagnostics development. Its "in-situ encoded bead array" (IEBA) technology allows industry and university users to realize the full potential of proteomics reliably as well as resource and cost efficiently. www.ayoxxa.com
In line with the company's strategy to commercialize its novel in-situ encoded bead array technology (IEBA), the funding will be used to scale-up the production of AYOXXA's proprietary biochips as well as to achieve international commercial readiness.
"I am pleased that we were able to close this round in a macro- environment that currently is very challenging, finding funding for young companies has become extremely difficult.", comments Dr. Andreas Schmidt, CEO of AYOXXA, "Beyond the financial assets, we will benefit from the expanded network in the biotechnology, pharmaceutical and enabling technology field. This will facilitate effective commercialization of our IEBA technology in the near future." he adds.
"The overall concept of AYOXXA has convinced us and the patented new multiplex platform already generates big interest in the pharmaceutical and biotech industries. The combination of innovative biotechnology and information technology also fits well with Creathor's investment strategy", says Karlheinz Schmelig, Managing Partner at Creathor Venture.
"The international team, a high-performance, easy-to-use platform and a renowned investor base will help AYOXXA to develop their technology to a gold standard in protein research. I am looking forward to work with the AYOXXA team as an advisory board member", adds Christian Leikert, Investment Manager at Creathor Venture In order to complement the co-founders Dr. Andreas Schmidt (CEO) and Prof. Dieter Trau (CSO) AYOXXA has attracted experienced leadership for its corporate executive management team and supervisory board:
Dr. Markus Zumbansen, Vice President Research and Development, has more than ten years of experience in the development of platform technologies. Before joining AYOXXA he worked in different R&D positions within the biotech industry, Miltenyi Biotec being his last station.
Michael Rasche, newly appointed Corporate Vice President Global Commercial Operations is now leading all activities in the area of marketing, sales and business development. He has an international background with 23 years of experience in leading pharma and diagnostics companies.
Rodney Turner, until recently Vice President of Corporate Business Development for Life Technologies Corporation, joins AYOXXA's supervisory board as of immediately. Mr. Turner graduated with a BA from Rice University. He had a leading role in the acquisitions of AMG Advanced Microscopy Group, BAC The Bioaffinity Company, BioTrove, Stokes Bio, GeneArt AG, Ambion, and several others. His extensive experience in life science tools companies will primarily help to accelerate product introduction into new markets across the research segments.
About AYOXXA Biosystems
AYOXXA Biosystems, an international biotech company based in Cologne, Germany and Singapore has developed a proprietary Technology platform for multiplexed protein analysis. Core to the cutting-edge system is a bead-based technology that yields 10,000-fold more data points than a standard ELISA. Together with the lowest sample volume in multiplex protein analysis history, very good accuracy and data robustness, high data throughput and readout with equipment existing already in your lab, AYOXXA will innovate biomedical research, pharmacological screening and preclinical diagnostics development. Its "in-situ encoded bead array" (IEBA) technology allows industry and university users to realize the full potential of proteomics reliably as well as resource and cost efficiently. www.ayoxxa.com
